• WHO WE ARE

    Overview

    Headquartered in Cape Town (South Africa), PHARMA DYNAMICS was founded in 2001 by CEO Paul Anley and is today one of the most trusted names in generic pharmaceuticals among healthcare practitioners and patients alike.

    Our cardiovascular (CVS) products continue to be the most prescribed portfolio for heart related conditions in the country, which bears testament of our passion for quality and the efficacy of our products – all of which are designed around the needs of millions of Southern Africans.

    In addition to our leading CVS business, we also provide central nervous system-, paediatric- and a growing range of over-the-counter products, which include top brands in the cold and flu, allergy, heartburn and immune booster categories. We furthermore specialise in critical hospital products, such as antibiotics used in intensive care settings, as well as male and female speciality healthcare portfolios, all of which are prescribed and recommended by thousands of doctors and pharmacists.

    PHARMA DYNAMICS is wholly owned by Lupin Limited after an initial majority stake acquisition by this transnational pharmaceutical company in 2008. The equity acquisition by Lupin – which produced a wide range of quality, affordable generic and branded formulations and active pharmaceutical ingredients (APIs) for developed and developing markets – has given PHARMA DYNAMICS increased access to international research and development, and has contributed significantly to its strong foothold in the Southern African market.

    Read More

    Lupin is an innovation led pharmaceutical company producing and developing a wide range of formulations as well as biotechnology products and APIs globally. Lupin is the 5th largest and fastest growing top 5 generics player in the US (5,3% market share by prescriptions, IMS Health) and the 3rd largest Indian pharmaceutical company by sales. For the financial year ended March 2015, Lupin’s consolidated revenues and profit after tax were USD 1,97-billion and USD 376-million respectively*.

    * Lupin (Pty) Ltd Financial Statements ending March 2015.